These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11010656)

  • 1. New drug applications; drug master files. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jan; 65(8):1776-80. PubMed ID: 11010656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drug applications and new drug applications--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(28):6854-62. PubMed ID: 10177736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational new drug applications; amendment to clinical hold regulations for products intended for life-threatening diseases and conditions. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jun; 65(106):34963-71. PubMed ID: 11010726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.
    Fed Regist; 1998 Jun; 63(120):34188-90. PubMed ID: 10180293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug applications and abbreviated new drug applications; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Mar; 74(43):9765-6. PubMed ID: 19418639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental assessments and findings of no significant impact--FDA. Notice.
    Fed Regist; 1998 May; 63(95):27300-3. PubMed ID: 10179346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin products for oral use; revocation of conditions for marketing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(123):42992-7. PubMed ID: 12120661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
    Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delegations of authority and organization; new drug applications--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Jun; 47(120):26822-3. PubMed ID: 10255868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.